arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Verrica Pharmaceuticals Inc.

VRCA
$5.16 ▼ -0.18 (-3.46%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
38 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

Verrica Pharmaceuticals Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $109.9M
Dividend Yield
Revenue Growth 46.1%
Op. Margin -193.4%
ROIC -47.8%
FCF / Share $-0.43
Trailing P/E
Price / Book 5.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

38-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$5.02M
↑ +46.1%
Net Income Profit after all expenses
$-9.68M
↑ +0.6%
Operating Margin Operating profit as % of sales
-193.4%
↓ -36.9% 7th
FCF / Share Free cash flow per share
$-0.43
↑ +67.8%
Long-Term Debt Long-term obligations
$0.00
↓ -100.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
6
Returns
12
Financial Health
69
Cash Quality
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 38 quarters